Financial Performance - The company's total revenue is 130 million, ranking 130 among disclosed peers [1] - The net profit attributable to shareholders is -162 million, ranking 141 among disclosed peers [1] - The net cash flow from operating activities is -194 million, ranking 139 among disclosed peers [1] Financial Ratios - The latest debt-to-asset ratio is 16.55%, an increase of 3.95 percentage points from the previous quarter and 5.91 percentage points from the same period last year [3] - The latest gross profit margin is 73.17%, a decrease of 5.70 percentage points from the previous quarter and 5.39 percentage points from the same period last year [3] - The latest return on equity (ROE) is -8.92%, ranking 135 among disclosed peers, a decrease of 0.49 percentage points from the same period last year [3] Earnings and Turnover - The diluted earnings per share is -0.29, ranking 135 among disclosed peers [4] - The latest total asset turnover ratio is 0.06, ranking 136 among disclosed peers [4] - The latest inventory turnover ratio is 4.49 times, a decrease of 5.37 times from the same period last year, representing a year-on-year decline of 54.46% [4] Shareholder Information - The number of shareholders is 25,500, with the top nine shareholders holding 211 million shares, accounting for 37.08% of the total share capital [4] - The largest shareholder is PAN KE, holding 22.83% of the shares [4]
亚虹医药(688176.SH):2025年中报净利润为-1.62亿元